Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 132Pancreatic Neoplasms 36Esophageal Neoplasms 19Biliary Tract Neoplasms 18Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 10Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Gastrointestinal Neoplasms 6Nasopharyngeal Carcinoma 5Colonic Neoplasms 5Adenocarcinoma 5Neoplasms 4Head and Neck Neoplasms 4Advanced Pancreatic Cancer 4Advanced Gastric Cancer 4Recurrence 3Rectal Neoplasms 3Gastric Adenocarcinoma 3Advanced Solid Tumors 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2NSCLC 2Locally Advanced Pancreatic Cancer 2Gastric Cancer Peritoneal Metastases 2Gallbladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2

Interventions

camrelizumab 3apatinib 2Oxaliplatin 2XELOX 1Taxes 1S 1 (combination) 1Laparoscopy 1Gastrectomy 1Conversion to Open Surgery 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Gastric Cancer × S 1 (combination) × Clear all
NCT05524974 2022-09-01

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Fujian Medical University

Phase 2 Not yet recruiting
203 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡